Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Jul 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called rituximab (RTX) for treating nephrotic syndrome in children. Nephrotic syndrome is a condition that causes the body to lose too much protein in the urine, leading to swelling and other health issues. The researchers are looking at how well RTX works over a year or more, especially for children who have not responded to other treatments. They will compare how often children relapse (have symptoms return) before and after using RTX, as well as monitor any side effects.

To be eligible for this study, children must be under 18 years old and have specific types of nephrotic syndrome that have not improved with other treatments. They should have complete medical data available and should be receiving RTX for the first time. Participants can expect regular follow-ups, which will include monitoring their health and any potential side effects from the medication. This study aims to gather important information that could help improve treatment options for children with nephrotic syndrome in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children clinically diagnosed with FRNS/SDNS/SRNS with complete clinical data;
• • age \< 18 years old;
• • For the first time using RTX treatment, and used in nephrotic syndrome ease;
• • The follow-up for 1 year or more.
• Exclusion Criteria:
• • Congenital or infantile nephrotic syndrome, secondary nephrotic syndrome (such as lupus nephritis, IgA nephropathy, purpura nephritis, hepatitis B nephritis, etc.);
• • Active stage of hepatitis, complicated with severe infection, severe deficiency of immune response, malignant diseases;
• • Estimated glomerular filtration rate (GFR) \<60mL/min/1.73m2.